Evaluating Haemodynamic Changes: Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction
Authors:
Open Access
- 29 April 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 11 (4) , 2451-2454
Abstract
Aims: Vericiguat has been used to treat patients with heart failure with reduced ejection fraction (HFrEF) who demonstrated worsening heart failure despite treatment with other guideline-directed medical therapies. The haemodynamic effects of vericiguat remain unclear. Methods and results: This study enrolled 12 patients (median age, 63 [quartiles 53.5, 70] years; 16.7%(N=2) women) with symptomatic HFrEF (New York Heart Association functional class II–IV) who demonstrated worsening heart failure despite treatment with the four foundational guideline-recommended therapies between March and December 2022, with follow-ups completed in June 2023. A balloon-tipped pulmonary artery thermodilution catheter was placed in the right internal jugular vein to perform right heart catheterisation (RHC) on day 1. Haemodynamic data were acquired before and after vericiguat intake (2.5 mg) on days 2 and 3. The data on days 2 and 3 were averaged. RHC was repeated on day 105 (37, 168). Oral intake of vericiguat 2.5 mg decreased mean pulmonary artery pressure (19.3 [14.3, 26.8] mmHg) and pulmonary artery wedge pressure (PAWP) (11 [7.5, 15] mmHg) before the intake to mean pulmonary artery pressure (17.5 [12.5, 24] mmHg) and PAWP (9.3 [6.8, 14] mmHg) at 30 min after (both P < 0.05). Reduction in PAWP was also found from 14.5 [9.5, 19.5] mmHg on day 1 to 9.5 [6.5, 12.5] mmHg on day 105 (37, 168) (P < 0.05), when vericiguat was titrated to 2.5 mg 25% (N = 3), 5 mg 50% (N = 6), and 10 mg 25% (N = 3). Conclusions: The consistent reduction in PAWP underscores the well-tolerated nature of vericiguat and its potential to enhance cardiac performance in patients with HFrEF.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K07776)
- Japan Society for the Promotion of Science (23K06843)
- Japan Society for the Promotion of Science (20K07776)
- Japan Society for the Promotion of Science (23K06843)
This publication has 12 references indexed in Scilit:
- Inhaled Nitric Oxide Testing in Predicting Prognosis in Pulmonary Hypertension Due to Left-Sided Heart DiseasesESC Heart Failure, 2023
- Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trialEuropean Heart Journal, 2022
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesCirculation, 2022
- Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjectsEuropean Journal of Clinical Pharmacology, 2020
- Vericiguat in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2020
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection FractionJAMA, 2015
- Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular DysfunctionCirculation, 2013
- Riociguat for the Treatment of Chronic Thromboembolic Pulmonary HypertensionNew England Journal of Medicine, 2013
- Riociguat for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Secondary Pulmonary Hypertension in Chronic Heart FailureCirculation, 2000